GlassScriptPhysician profile
Craig H Marcus
NPI 1386642247
$23,121.97
in general payments reported to CMS, 2019-2025
20 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,028 · 2020: $8,903 · 2021: $4,126 · 2022: $549 · 2023: $900 · 2024: $1,125 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,515.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $17,472.17 | 2019-2021 | |
| Abbvie INC. | $1,739.16 | 2022-2025 | |
| Alcon Vision LLC | $1,151.57 | 2019-2025 | Hydrus Microstent, Simbrinza, Rocklatan |
| New World Medical,INC. | $820.13 | 2019-2024 | Streamline, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Allergan, INC. | $501.43 | 2019-2022 | |
| Glaukos Corporation | $350.39 | 2019-2025 | Idosetr |
| Tarsus Pharmaceuticals, INC. | $209.48 | 2025 | Xdemvy |
| Sight Sciences, INC. | $171.77 | 2019-2023 | Omni Surgical System |
| Kala Pharmaceuticals, INC. | $165.82 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $118.73 | 2023 | Syfovre |
| Oyster Point Pharma, INC. | $88.15 | 2023-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $64.80 | 2022-2025 | Vyzulta, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $61.76 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $42.35 | 2023-2024 | Cequa |
| Horizon Therapeutics Plc | $38.62 | 2023 | Tepezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $37.25 | 2019 | |
| Harrow Eye, LLC | $24.30 | 2024 | Vevye |
| Thea Pharma INC. | $23.67 | 2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $21.13 | 2019 | |
| Amgen INC. | $19.29 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Marcus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.